Logo
Profhilo Face Lift Treatment (PROFHILO H+L 1 x 2 ml)

Profhilo Face Lift Treatment (PROFHILO H+L 1 x 2 ml)

Profhilo

Injectable aesthetic medical device
  • CE Marked Class III sterile injectable hyaluronic acid medical device for intradermal/superficial subcutaneous use.
  • Manufactured using NAHYCO hybrid technology to produce stabilised hybrid cooperative complexes of high and low Molecular Weight HA without BDDE or similar chemical cross Linkers.
  • Produced under IBSA pharmaceutical and medical device quality systems compliant with applicable EU medical device regulations and relevant ISO/EN standards.
Facial bioremodeling hyaluronic acid injectable (skin booster)

Description

Profhilo Face Lift Treatment (PROFHILO H+L 1 x 2 ml) is a CE-marked injectable hyaluronic acid medical device from IBSA Derma designed for facial skin bioremodeling rather than traditional volumising fill. Each pre-filled 2 ml syringe contains 64 mg of ultrapure hyaluronic acid (32 mg high molecular weight + 32 mg low molecular weight) in the form of stabilised hybrid cooperative complexes created with NAHYCO thermal technology and free from BDDE and other chemical cross-linking agents. Marketed as an ultra-pure, high-concentration deep skin moisturiser, Profhilo provides intense hydration, improves texture and fine lines, and remodels areas of facial laxity such as the cheeks, chin and perioral region. Using the Bio Aesthetic Points (BAP) injection technique, it diffuses widely through the superficial subcutaneous/deep dermal layers to enhance skin quality, elasticity and firmness with a very natural, non-volumised result.

Bnefits

  • High concentration of ultrapure hyaluronic acid: 64 mg HA in a 2 ml pre-filled syringe (32 mg high molecular weight + 32 mg low molecular weight).
  • Utilises NAHYCO hybrid technology to create stabilised hybrid cooperative complexes of HA without BDDE or other chemical cross-linkers, improving safety and biocompatibility.
  • Acts as a deep skin moisturiser and bioremodeling agent rather than a traditional filler, focusing on hydration, tissue quality, elasticity and subtle lifting.
  • Excellent for improving fine lines, skin texture, radiance and laxity across the mid- and lower face, neck and décolleté, with off-label use on hands, upper arms and knees in professional practice.
  • Wide tissue diffusion from a limited number of injection points (BAP technique) reduces the number of injections needed and helps achieve a uniform, natural-looking outcome.
  • Compatible with other aesthetic treatments such as dermal fillers, PRP and botulinum toxin as part of combined anti-ageing protocols when planned by a qualified practitioner.
  • Non–chemically cross-linked HA formulation supports a favourable safety profile and rapid integration into the tissue.
  • Clinically reported longevity of results around 6–9 months or longer after a standard two-session course, with many clinics quoting 9–12 months depending on patient factors.

Indications

  • Tissue remodelling and improvement of skin laxity in the face, especially the malar-zygomatic and sub-malar regions (cheeks, jowl area and lower face).
  • Restoration of skin firmness, tone and elasticity in the neck and décolleté.
  • Improvement of skin hydration, texture and fine lines in photo- and chrono-aged skin.
  • Enhancement of overall facial radiance and suppleness where a non-volumising, skin-quality-focused injectable is desired.
  • In professional practice, it may also be used on other areas with mild to moderate laxity such as hands, upper arms and knees, in accordance with the IFU and local regulatory guidance.

Composition

  • Hyaluronic acid sodium salt: 64 mg per 2 ml (32 mg high molecular weight HA + 32 mg low molecular weight HA).
  • Sodium chloride.
  • Sodium phosphate (buffering agents).
  • Water for injections.

Formulation

  • Crystal-clear, sterile, apyrogenic, viscoelastic gel of hyaluronic acid sodium salt in stabilised hybrid cooperative complexes (HCC) formed from high and low molecular weight HA.
  • Total HA concentration: 64 mg/2 ml (3.2% w/v).
  • Produced via NAHYCO thermal technology without BDDE or other chemical cross-linking agents.
  • Supplied as a single-use, pre-filled 2 ml glass syringe for deep dermal/superficial subcutaneous injection.
  • Designed for wide tissue diffusion and cohesive behaviour, with minimal volumising effect and strong hydrating/bioremodeling action.

Packaging

  • Each box contains:
  • • 1 x pre-filled 2 ml glass syringe of Profhilo (64 mg/2 ml hyaluronic acid sodium salt).
  • • 2 x Terumo needles 29G x 13 mm (or equivalent, depending on market).
  • • 1 x Instructions for Use (IFU) leaflet.
  • • 1 x Patient Information Leaflet (PIL) / implant card (market dependent).
  • • 2 x product traceability labels for medical records and patient documentation.

Usage

  • Profhilo Face Lift Treatment (PROFHILO H+L) is a Class III medical device and must only be administered by qualified medical professionals experienced in facial anatomy and injectable procedures.
  • Prior to treatment, take a full medical history and obtain informed consent. Assess the face and, where appropriate, neck or other planned areas for degree of laxity and treatment suitability.
  • Inspect the blister and outer packaging; use only if intact and within the stated expiry date. Do not use if the solution is cloudy, discoloured or contains particles.
  • Attach one of the supplied 29G needles securely to the Luer-lock of the syringe under aseptic conditions, then gently expel any air bubble and a small amount of product to prime the needle if necessary.
  • Inject into the deep dermal/superficial subcutaneous layer using the Bio Aesthetic Points (BAP) technique for the face: typically 5 injection points per side (total 10 points), with 0.2 ml per point (total 2 ml per session).
  • For neck and other areas, follow manufacturer guidance and recognised training protocols (adapted BAP or linear point techniques) while strictly observing safe anatomical planes and avoiding vascular structures.
  • Standard treatment course: 2 sessions of 2 ml each, approximately 4 weeks (1 month) apart. Additional maintenance sessions can be performed according to clinical judgement, often every 6–9 months.
  • Do not inject intravascularly, intramuscularly, into tendons, or into areas with active inflammation, infection, chronic skin disease or previous permanent fillers unless safety is clearly established.
  • After injection, lightly massage the treated areas if necessary to aid even distribution; avoid aggressive manipulation.
  • Post-treatment advice typically includes avoiding intense heat or cold exposure, vigorous exercise, saunas, steam rooms, sunbeds and direct UV exposure for several days; recommend high-SPF sun protection on exposed treated areas.
  • Dispose of the syringe and needles immediately after use in an approved sharps container; any remaining product in an opened syringe must be discarded and must not be reused or resterilised.

Contraindications

  • Known hypersensitivity or allergy to hyaluronic acid or any of the excipients (sodium chloride, sodium phosphate, water for injections).
  • Presence of active skin disease, infection or inflammation (e.g. dermatitis, bacterial or viral infection such as herpes simplex) at or near the intended injection sites.
  • History of severe allergy or anaphylactic reactions to injectable biomaterials.
  • Pregnancy or breastfeeding, as safety data are insufficient and use is generally not recommended in these populations.
  • Autoimmune diseases or patients receiving immunosuppressive therapy, unless the prescribing physician judges that potential benefits outweigh risks.
  • Uncontrolled coagulation disorders or concurrent use of anticoagulant/antiplatelet therapy that significantly increases the risk of bleeding or haematoma, without prior medical evaluation.
  • Do not inject into blood vessels, muscles, tendons, mammary tissue, or in areas with permanent implants or fillers where interactions and safety cannot be assured.
  • Treatment is not recommended immediately after medium/deep chemical peels, laser resurfacing or other aggressive procedures in the same area without adequate healing.

Adverse Effects

  • Typical, usually transient injection-site reactions including redness (erythema), swelling, mild to moderate pain or tenderness, warmth, pruritus (itching) and small haematomas or bruising.
  • Transient palpable lumps or nodules at injection points due to gel placement and local oedema, which usually resolve spontaneously over a few days to weeks.
  • Less commonly, local inflammatory reactions, prolonged swelling or induration may occur and should be assessed and managed by the treating clinician.
  • As with all injectable HA devices, rare but serious complications include infection, abscess formation, vascular compromise and, in very rare cases, tissue necrosis in the event of intravascular injection or significant vascular compression.
  • Hypersensitivity reactions are rare but possible; practitioners must be prepared to recognise and treat acute allergic reactions in accordance with local emergency protocols.

Storage Conditions

  • Store the unopened Profhilo syringe in its original blister and outer carton at a controlled room temperature, generally between 2 °C and 25 °C as indicated on the packaging.
  • Protect from direct sunlight, excessive heat and moisture. Do not freeze.
  • Do not use after the expiry date printed on the carton and syringe label.
  • Once the sterile blister is opened, use the syringe immediately; any unused product must be discarded and must not be stored for later use.
  • Keep out of the reach and sight of children. Do not resterilise the device.

Duration

The standard protocol consists of two treatment sessions of 2 ml each, spaced approximately 4 weeks apart. Clinical effects on skin hydration, texture and laxity commonly persist for about 6\u20139 months and may last up to 12 months depending on patient age, skin quality, treatment area and lifestyle. Maintenance sessions are typically recommended every 6\u201312 months according to clinical assessment.

Onset

Improved hydration and subtle radiance can appear within days to a few weeks after the first session, with more visible improvements in firmness, elasticity and fine lines usually becoming evident 4\u20138 weeks from the start of treatment, particularly after the second session.

Browse more Injectable aesthetic medical device

Top Treatments

Top Cities in the UK